Ascendis Pharma reclaims full control of its TransCon metabolic pipeline from Novo Nordisk, trading partnership security for the potential to capture higher future commercial returns.
Ascendis Pharma regains exclusive rights to TransCon metabolic and cardiovascular products after terminating its collaboration with Novo Nordisk, regaining control but facing development costs and clinical uncertainties.
Novo Nordisk terminates its collaboration with Ascendis Pharma, returning TransCon Semaglutide rights with no ongoing financial obligations, which likely has limited impact on Novo Nordisk's broader semaglutide franchise.
Ascendis Pharma has reclaimed exclusive rights to its TransCon metabolic and cardiovascular portfolio, including the once-monthly semaglutide candidate, following the termination of its partnership with Novo Nordisk. While the move grants Ascendis full strategic control and potential long-term upside, it shifts the full burden of development costs and clinical execution back to the company.
The companies mutually terminated their agreement regarding TransCon metabolic and cardiovascular products, resulting in the full reversion of rights to Ascendis Pharma without further financial obligations.
The company aims to establish a once-monthly dosing regimen for obesity and type 2 diabetes that maintains efficacy and safety comparable to existing treatments.